Deborah Dunsire is breaking an old pattern: The definition of madness is doing the same thing over and over, expecting a different outcome
In her first three years at Lundbeck, one of Deborah Dunsire's missions has been to rethink the pipeline and the way in which clinical trials are carried out, attempting to avoid more big and costly failures in clinical development at the company.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY DANIEL PEDERSEN
Few and far between have been product launches at Lundbeck the past few years, including the three years led by Deborah Dunsire, with the only new launch being that of Vyepti, which is – for Lundbeck – a relatively new area: migraine.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Lundbeck presents positive results from migraine drug trial
For subscribers
New Lundbeck candidate to kick off R&D division
For subscribers
